Join live meetings with leading clinicians and researchers. Submit questions about cases and disease management.
Karl E. Anderson, MD is a graduate of the Johns Hopkins University School of Medicine. He completed his residency training in internal medicine and postgraduate training in gastroenterology at Vanderbilt University Hospital and New York Hospital Cornell Medical Center. Prior to joining the University of Texas Medical Branch in 1987, Dr. Anderson held faculty appointments at the Rockefeller University, Cornell University Medical College, and New York Medical College. He is currently a Professor in the Departments of Preventive Medicine and Community Health and Internal Medicine within the Division of Gastroenterology and Hepatology. He is also a member of the Institute for Translational Sciences and the Academy of Research Mentors. Dr. Anderson serves as Director of the Clinical Science Program in the Graduate School of Biomedical Sciences and is an active clinical investigator on the Institute for Translational Sciences Clinical Research Center, where he also holds the role of Associate Director. His research program is supported by the NIH, FDA, foundations, and industry partners. Internationally recognized for his work in the human porphyrias, Dr. Anderson's research and clinical expertise focus on the diagnosis, pathophysiology, and treatment of porphyria disorders, including acute intermittent porphyria. Through his leadership in translational research and clinical investigation, he has played a pivotal role in advancing evidence based therapies and improving care for patients with rare metabolic and hematologic conditions.
Catherine Broome, MD is a Professor of Medicine in the Division of Hematology/Oncology at MedStar Georgetown University Hospital in Washington, DC. She is board-certified in internal medicine, hematology, and medical oncology. Catherine Broome, MD has been on staff at the Georgetown Lombardi Comprehensive Cancer Center for over a decade, where she specializes in benign hematology. Her clinical expertise encompasses a range of hematologic disorders, including immune thrombocytopenia (ITP), autoimmune hemolytic anemia, cold agglutinin disease, hemophagocytic lymphohistiocytosis, paroxysmal nocturnal hemoglobinuria (PNH), and pure red cell aplasia. Catherine Broome, MD is actively involved in clinical research and offers patients the opportunity to participate in clinical trials for various hematologic conditions. In addition to her clinical work, Catherine Broome, MD serves as an associate professor in the Department of Medicine at Georgetown University, contributing to the education and training of future physicians. She also participates in the hospital's safety committee, focusing on developing programs and policies to ensure patient safety throughout MedStar Health. Catherine Broome, MD's approach to patient care emphasizes collaboration, providing patients with the most up-to-date information and treatment options, and developing personalized treatment plans that consider all aspects of the patient's life.
Susan O'Brien, MD is a Professor of Medicine in the Division of Hematology/Oncology at the University of California, Irvine, where she previously served as Associate Director for Clinical Science at the Chao Family Comprehensive Cancer Center. She earned her medical degree at the University of Medicine and Dentistry of New Jersey and completed her fellowship in Hematology/Oncology at MD Anderson Cancer Center, where she later held the Ashbel Smith Professorship of Medicine. Internationally recognized for her expertise in leukemia, Susan O'Brien, MD has been instrumental in developing novel therapies for both acute and chronic forms of the disease, with a particular focus on chronic lymphocytic leukemia (CLL). She was a leading investigator in the early clinical trials of ibrutinib (Imbruvica), a groundbreaking therapy for CLL, and has served as principal investigator on numerous clinical studies. Susan O'Brien, MD has authored more than 900 peer-reviewed publications, making her one of the most highly cited researchers in the field of leukemia. She also serves in leadership roles with cooperative oncology groups and contributes to patient advocacy through her work with organizations such as the CLL Society. Her achievements have been recognized with multiple honors, including the Giant of Cancer Care Award in Leukemia, the Binet–Rai Medal for innovation in CLL research, and the Excellence in Scientific Service Award from the Leukemia & Lymphoma Society.
ASH 2026 is poised to bring important new developments across the leukemia treatment landscape, and this session is designed to distill the data that matters most for practice. We are privileged to bring together a distinguished panel of nationally recognized leukemia experts who will review the highest-impact presentations across chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Drawing on deep clinical and research expertise, our faculty will spotlight practice-changing trials, emerging targeted and immune-based therapies, and evolving standards of care, translating complex data into actionable guidance. Attendees will leave with a clear understanding of how the latest findings apply to real-world patient management. Designed for hematologists, oncologists, advanced practice providers, fellows, and other members of the hematology/oncology care team.
Non-malignant hematology is advancing rapidly, with new therapies and refined management strategies reshaping how common and complex disorders are treated. We are delighted to convene a talented panel of expert classical hematologists who will review the most clinically relevant data anticipated from ASH 2026, covering bone marrow failure, immune thrombocytopenia (ITP), thrombotic thrombocytopenic purpura (TTP), and bleeding disorders. Bringing extensive clinical experience to each topic, our faculty will highlight emerging treatment options, updated diagnostic and management approaches, and the practical implications of the latest evidence. Attendees will leave with actionable insights they can apply directly to the care of their patients. Designed for hematologists, oncologists, advanced practice providers, fellows, and other members of the hematology/oncology care team. Faculty: Taha Bat, MD | UT Southwestern | Bone Marrow Failure Ibrahim Ibrahim, MD | UT Southwestern | Immune Thrombocytopenia (ITP) & Thrombotic Thrombocytopenic Purpura (TTP) Yu-Min Shen, MD | UT Southwestern | Bleeding Disorders
Myeloma care is evolving faster than ever, with an expanding array of novel agents, immune-based therapies, and combination strategies redefining outcomes. We are proud to bring together a renowned faculty of myeloma and amyloidosis experts who will review the most significant data anticipated from ASH 2026, including advances in frontline and relapsed/refractory treatment, patient selection, and minimal residual disease–guided approaches, alongside key updates in the diagnosis and management of amyloidosis. Through focused, practice-oriented discussion led by these leaders in the field, attendees will gain a clear picture of the findings most likely to shape myeloma care going forward. Designed for hematologists, oncologists, advanced practice providers, fellows, and other members of the hematology/oncology care team. Faculty: Larry Anderson, MD | UT Southwestern | Multiple Myeloma Adeel Khan, MD | UT Southwestern | Multiple Myeloma Samer Al Hadidi, MD | UT Southwestern | Amyloidosis
In their comprehensive discussion titled "Aplastic Anemia and Transplant," Richard Childs, MD and Taha Bat, MD provide crucial insights into the diagnosis and treatment of aplastic anemia, with a significant focus on various transplant considerations. They illustrate their points using a detailed case study of a 38-year-old female diagnosed with severe aplastic anemia. Throughout the talk, they meticulously cover essential aspects such as diagnostic procedures, the critical urgency of initiating transplant, the process of selecting an appropriate donor, the specifics of conditioning regimens, and vital post-transplant management strategies. Their presentation aims to guide medical professionals through the complex decision-making process involved in effectively managing patients with aplastic anemia.
This video features Mrinal Patnaik, MD of Mayo Clinic and Taha Bat, MD discussing clonal cytopenias of undetermined significance (CCUS) and myelodysplastic syndromes (MDS), covering diagnostic criteria, management strategies, and the clinical implications of clonal hematopoiesis. Mrinal Patnaik, MD delves into the nuances of distinguishing between these conditions and their impact on treatment access. The session covers the importance of clinical correlation, detailed considerations for clonal hematopoiesis workup in patients with solid malignancies, and the rationale behind the 2% Variant Allele Fraction (VAF) cutoff. The discussion highlights risk stratification models, MDS-defining cytogenetic abnormalities, and explores clinical implications beyond cytopenia, including inflammatory symptoms and increased cardiovascular risk.
This video features a discussion between Ayalew Tefferi, MD, a Professor of Medicine and leading hematologist at Mayo Clinic specializing in Myeloproliferative Neoplasms (MPN), and Taha Bat, MD. Taha Bat, MD guides the conversation by presenting clinical cases and asking questions about the diagnostic workup, risk stratification, and treatment of Essential Thrombocythemia (ET). Ayalew Tefferi, MD provides in-depth insights into ET, including its clinical presentation, diagnostic challenges, and prognostic factors, emphasizing the importance of considering secondary causes of thrombocytosis before diagnosing MPN. He highlights the significance of host-related factors and mutations in determining patient longevity. The collaborative discussion offers valuable insights into the complexities of ET diagnosis and management through clinical cases and expert opinions on controversial topics.
